The short answer
Keep an oral iron preparation separate from risedronate. Both standard risedronate and delayed-release Atelvia instructions place iron at a different time of day because it can interfere with absorption. A timing adjustment is different from abandoning prescribed treatment for iron deficiency.
What this answer covers
Oral iron preparations with oral risedronate sodium. Intravenous iron is outside the intestinal co-administration concern assessed here.
- Supplement or preparation
- Iron
- Medication ingredient
- risedronate
Why does this combination need attention?
Iron is specifically named in the administration recommendations for both risedronate formulations. This provides a clear timing precaution, but the labels do not quantify the loss of absorption for individual ferrous or ferric salts. The evidence therefore supports formulation-based prescribing guidance rather than an identical measured effect for every iron product.
How should the doses be scheduled?
For standard immediate-release risedronate, take the medicine before breakfast with plain water and observe the initial 30-minute wait before food or oral products. The labels additionally place calcium, antacids, magnesium and iron at another time of day. Atelvia is instead taken immediately after breakfast. Confirm the formulation before applying either routine; delayed release does not remove the mineral separation instructions.
What should I discuss with my pharmacist?
A pharmacist can help fit iron around meals, other medicines and the bisphosphonate dosing day. Include iron contained in multivitamins or prenatal products. Keep the prescribed replacement dose and treatment goal clear. After an accidental same-time dose, seek advice instead of taking an extra risedronate tablet.
What are the limits of the evidence?
The delayed-release efficacy trial showed acceptable bone-density responses with supplements taken at another meal. It does not demonstrate same-time compatibility with iron. No direct iron-salt comparison or reliable iron-specific fracture outcome was identified in the inspected sources. The best-supported concern is reduced oral drug absorption, with a schedule determined by the actual risedronate formulation.
Evidence and practical considerations
Absorption & effectiveness
Keep an oral iron preparation separate from risedronate. Both standard risedronate and delayed-release Atelvia instructions place iron at a different time of day because it can interfere with absorption. A timing adjustment is different from abandoning prescribed treatment for iron deficiency.
- Exact scope
- Oral iron preparations with oral risedronate sodium. Intravenous iron is outside the intestinal co-administration concern assessed here. with oral immediate-release risedronate sodium; oral delayed-release risedronate sodium
- Medication form and route
- oral immediate-release risedronate sodium; oral delayed-release risedronate sodium
- Timing or duration
- Timing applies on each prescribed oral dose day. Nutrient adequacy is an ongoing treatment consideration. Clinical trial durations and limitations are recorded in each source.
What remains uncertain
- The delayed-release efficacy trial showed acceptable bone-density responses with supplements taken at another meal. It does not demonstrate same-time compatibility with iron. No direct iron-salt comparison or reliable iron-specific fracture outcome was identified in the inspected sources. The best-supported concern is reduced oral drug absorption, with a schedule determined by the actual risedronate formulation.
Factors that may matter: Medication route and release formulation; Supplement mineral content and chemical preparation; Timing relative to breakfast and other oral products.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients taking immediate-release oral risedronate sodium tablets for approved bone indications.
The medicine is taken before breakfast and other oral products with an initial 30-minute interval. Calcium, antacids, magnesium products and iron are scheduled at a different time of day. Calcium and vitamin D adequacy is recommended, with supplementation if dietary intake is inadequate.
How this applies: Applies to oral iron-containing medicinal or supplement products under the stated medication formulation. Individual salt effects and quantitative outcome differences are not established. Exact scope: Oral iron preparations with oral risedronate sodium. Intravenous iron is outside the intestinal co-administration concern assessed here.
Product instructions and class-based absorption precautions do not quantify every individual mineral salt. They must not be substituted for delayed-release dosing instructions.
Source 2: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Postmenopausal women receiving delayed-release oral risedronate 35 mg; absorption crossover included 101 postmenopausal women.
Co-administration of the combination supplement reduced risedronate exposure approximately 38%. The label places calcium, antacids, magnesium products and iron at a different time of day and specifies Atelvia immediately after breakfast.
How this applies: Applies to oral iron-containing medicinal or supplement products under the stated medication formulation. Individual salt effects and quantitative outcome differences are not established. Exact scope: Oral iron preparations with oral risedronate sodium. Intravenous iron is outside the intestinal co-administration concern assessed here.
The absorption study used a combined calcium-vitamin D product and cannot isolate vitamin D, another mineral or every calcium salt. The 38% estimate is not transferable to all formulations or supplements.
Source 3: peer-reviewed randomized clinical trial
europepmc.org · Source check Sep 10, 2026
Population: 922 treated postmenopausal women with osteoporosis; immediate-release daily group n=307, delayed-release before-breakfast n=308 and after-breakfast n=307.
Delayed-release regimens were non-inferior on lumbar-spine bone mineral density. The supplement instructions deliberately separated calcium and vitamin D from risedronate.
How this applies: Direct evidence for risedronate formulation schedules, with separated calcium/vitamin D use. It does not test simultaneous iron co-administration. Exact scope: Oral iron preparations with oral risedronate sodium. Intravenous iron is outside the intestinal co-administration concern assessed here.
Formulation efficacy study, not a simultaneous mineral co-administration trial. All subjects received supplements; their necessity, independent effects and optimal individual doses were not randomized. The older before-breakfast trial arm does not override current Atelvia after-breakfast instructions.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current oral formulation labels, route boundaries and original dosing evidence assessed. Exact existing statements adjudicated and article prepared. Clinical sign-off not recorded. | |
| Research summary published |
Article revision: 51d479acc8afdef4
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.